pharmaceutical-investing Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality - Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
pharmaceutical-investing Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
pharmaceutical-investing Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
pharmaceutical-investing Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
pharmaceutical-investing Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Zscaler 2026 AI Threat Report: 91% Year-over-Year Surge in AI Activity Creates Growing Oversight Gap for Global Enterprises
Vizsla Copper Receives Letter of Support from Alaska Governor and Outlines 2026 Exploration Plans at the Palmer Project
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
